CRO · Private company
IQVIA Pty Ltd
Track this companyFree. Adds IQVIA Pty Ltd to your Dealase workspace and tells you when its record changes.
Clinical trials259 recruiting or active
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Clinical trials25
- Anifrolumab Pregnancy StudyRECRUITING · started Jun 4, 2026ClinicalTrials.gov NCT07049653 · fetched Nov 12, 2026
- ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid TumorsCOMPLETED · started Jun 10, 2025ClinicalTrials.gov NCT06973161 · fetched Nov 12, 2026
- Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®TERMINATED · started Nov 21, 2024ClinicalTrials.gov NCT06498128 · fetched Nov 12, 2026
- THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of HypertensionNA · RECRUITING · started Oct 3, 2024ClinicalTrials.gov NCT06559891 · fetched Nov 12, 2026
- Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic CoughPHASE2 · ACTIVE_NOT_RECRUITING · started Sep 24, 2024ClinicalTrials.gov NCT06504446 · fetched Nov 12, 2026
- Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTSPHASE2 · TERMINATED · started Jun 20, 2023ClinicalTrials.gov NCT05918978 · fetched Nov 12, 2026
- [Study Evaluating the Efficacy and Safety of a Digital Therapeutic as an Adjunct to TAU in Postpartum Depression]NA · TERMINATED · started Nov 16, 2022ClinicalTrials.gov NCT05551195 · fetched Nov 12, 2026
- A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related PainPHASE2 · COMPLETED · started Oct 25, 2022ClinicalTrials.gov NCT05560646 · fetched Nov 12, 2026
- Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTSPHASE2 · COMPLETED · started Sep 23, 2022ClinicalTrials.gov NCT05633407 · fetched Nov 12, 2026
- Olorofim Aspergillus Infection StudyPHASE3 · COMPLETED · started Apr 29, 2022ClinicalTrials.gov NCT05101187 · fetched Nov 12, 2026
- Intraamniotic Administrations of ER004 to Male Subjects With X-linked Hypohidrotic Ectodermal DysplasiaPHASE2 · RECRUITING · started Apr 26, 2022ClinicalTrials.gov NCT04980638 · fetched Nov 12, 2026
- PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age With ScabiesPHASE4 · UNKNOWN · started Mar 4, 2022ClinicalTrials.gov NCT05310734 · fetched Nov 12, 2026
- An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)PHASE3 · COMPLETED · started Mar 1, 2022ClinicalTrials.gov NCT05243680 · fetched Nov 12, 2026
- Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral ContraceptivePHASE3 · TERMINATED · started Feb 17, 2022ClinicalTrials.gov NCT05264506 · fetched Nov 12, 2026
- Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus ErythematosusPHASE3 · ACTIVE_NOT_RECRUITING · started Jun 8, 2021ClinicalTrials.gov NCT04877691 · fetched Nov 12, 2026
- A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic PhenotypePHASE3 · COMPLETED · started Jan 26, 2021ClinicalTrials.gov NCT04718389 · fetched Nov 12, 2026
- Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.PHASE3 · COMPLETED · started Nov 21, 2020ClinicalTrials.gov NCT04625725 · fetched Nov 12, 2026
- Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking SurgeryPHASE3 · ACTIVE_NOT_RECRUITING · started Aug 25, 2020ClinicalTrials.gov NCT04498117 · fetched Nov 12, 2026
- SELUTION SLR™ 014 In-stent RestenosisNA · ACTIVE_NOT_RECRUITING · started Jul 6, 2020ClinicalTrials.gov NCT04280029 · fetched Nov 12, 2026
- Protection Against Emboli During Carotid Artery Stenting Using the Neuroguard IEP SystemNA · ACTIVE_NOT_RECRUITING · started Jun 12, 2020ClinicalTrials.gov NCT04201132 · fetched Nov 12, 2026
- US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)TERMINATED · started Dec 9, 2019ClinicalTrials.gov NCT04125290 · fetched Nov 12, 2026
- Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced MalignanciesPHASE1 · TERMINATED · started May 17, 2019ClinicalTrials.gov NCT03881488 · fetched Nov 12, 2026
- To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)PHASE1_PHASE2 · COMPLETED · started Sep 20, 2018ClinicalTrials.gov NCT03544281 · fetched Nov 12, 2026
- A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Mar 17, 2016ClinicalTrials.gov NCT02734004 · fetched Nov 12, 2026
- Expanded Access Program for OOS Obe-celAVAILABLEClinicalTrials.gov NCT06799221 · fetched Nov 12, 2026